K Schreuder1, A C M van Bommel2, K M de Ligt3, J H Maduro4, M T F D Vrancken Peeters5, M A M Mureau6, S Siesling7. 1. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; Department of Health Technology and Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Scientific Committee NABON Breast Cancer Audit (NBCA), The Netherlands. Electronic address: K.Schreuder@iknl.nl. 2. Scientific Committee NABON Breast Cancer Audit (NBCA), The Netherlands; Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands. 3. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 4. Scientific Committee NABON Breast Cancer Audit (NBCA), The Netherlands; Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. 5. Scientific Committee NABON Breast Cancer Audit (NBCA), The Netherlands; Department of Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 6. Scientific Committee NABON Breast Cancer Audit (NBCA), The Netherlands; Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute/University Medical Centre Rotterdam, Rotterdam, The Netherlands. 7. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; Department of Health Technology and Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Scientific Committee NABON Breast Cancer Audit (NBCA), The Netherlands.
Abstract
OBJECTIVES: Significant hospital variation in the use of immediate breast reconstruction (IBR) after mastectomy exists in the Netherlands. Aims of this study were to identify hospital organizational factors affecting the use of IBR after mastectomy for ductal carcinoma in situ (DCIS) or invasive breast cancer (BC) and to analyze whether these factors explain the variation. MATERIALS AND METHODS: Patients with DCIS or primary invasive BC treated with mastectomy between 2011 and 2013 were selected from the national NABON Breast Cancer Audit. Hospital and organizational factors were collected with an online web-based survey. Regression analyses were performed to determine whether these factors accounted for the hospital variation. RESULTS: In total, 78% (n = 72) of all Dutch hospitals participated in the survey. In these hospitals 16,471 female patients underwent a mastectomy for DCIS (n = 1,980) or invasive BC (n = 14,491) between 2011 and 2014. IBR was performed in 41% of patients with DCIS (hospital range 0-80%) and in 17% of patients with invasive BC (hospital range 0-62%). Hospital type, number of plastic surgeons available and attendance of a plastic surgeon at the MDT meeting increased IBR rates. For invasive BC, higher percentage of mastectomies and more weekly MDT meetings also significantly increased IBR rates. Adjusted data demonstrated decreased IBR rates for DCIS (average 35%, hospital range 0-49%) and invasive BC (average 15%, hospital range 0-18%). CONCLUSION: Hospital organizational factors affect the use of IBR in the Netherlands. Although only partly explaining hospital variation, optimization of these factors could lead to less variation in IBR rates.
OBJECTIVES: Significant hospital variation in the use of immediate breast reconstruction (IBR) after mastectomy exists in the Netherlands. Aims of this study were to identify hospital organizational factors affecting the use of IBR after mastectomy for ductal carcinoma in situ (DCIS) or invasive breast cancer (BC) and to analyze whether these factors explain the variation. MATERIALS AND METHODS:Patients with DCIS or primary invasive BC treated with mastectomy between 2011 and 2013 were selected from the national NABON Breast Cancer Audit. Hospital and organizational factors were collected with an online web-based survey. Regression analyses were performed to determine whether these factors accounted for the hospital variation. RESULTS: In total, 78% (n = 72) of all Dutch hospitals participated in the survey. In these hospitals 16,471 female patients underwent a mastectomy for DCIS (n = 1,980) or invasive BC (n = 14,491) between 2011 and 2014. IBR was performed in 41% of patients with DCIS (hospital range 0-80%) and in 17% of patients with invasive BC (hospital range 0-62%). Hospital type, number of plastic surgeons available and attendance of a plastic surgeon at the MDT meeting increased IBR rates. For invasive BC, higher percentage of mastectomies and more weekly MDT meetings also significantly increased IBR rates. Adjusted data demonstrated decreased IBR rates for DCIS (average 35%, hospital range 0-49%) and invasive BC (average 15%, hospital range 0-18%). CONCLUSION: Hospital organizational factors affect the use of IBR in the Netherlands. Although only partly explaining hospital variation, optimization of these factors could lead to less variation in IBR rates.
Authors: Wouter van der Schors; Ron Kemp; Jolanda van Hoeve; Vivianne Tjan-Heijnen; John Maduro; Marie-Jeanne Vrancken Peeters; Sabine Siesling; Marco Varkevisser Journal: BMJ Open Date: 2022-04-26 Impact factor: 3.006
Authors: E Heeg; M B Jensen; M A M Mureau; B Ejlertsen; R A E M Tollenaar; P M Christiansen; M T F D Vrancken Peeters Journal: Breast Cancer Res Treat Date: 2020-06-10 Impact factor: 4.872
Authors: Ennie Bijkerk; Sander M J van Kuijk; Arno Lataster; René R W J van der Hulst; Stefania M H Tuinder Journal: Breast Cancer Res Treat Date: 2020-04-28 Impact factor: 4.872
Authors: L S E van Egdom; K M de Ligt; L de Munck; L B Koppert; M A M Mureau; H A Rakhorst; S Siesling Journal: Breast Cancer Date: 2021-11-15 Impact factor: 4.239
Authors: E Heeg; J X Harmeling; B E Becherer; P J Marang-van de Mheen; M T F D Vrancken Peeters; M A M Mureau Journal: Br J Surg Date: 2019-08-06 Impact factor: 6.939